RDRashmi Ranjan Das

Rashmi Ranjan Das

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rashmi Ranjan Das has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serum procalcitonin as a predictor of severity of pneumonia in under-five children: A prospective observational study

    by Sapan Kumar Kanungo, Gobinda Hembram, Pratima Kumari Sahu, Rashmi Ranjan Das

    BACKGROUND Despite recent advancements in healthcare facilities, the early identification and assessment of pneumonia severity remain major challenges that affect clinical outcomes. These challenges emphasise the necessity for reliable biomarkers that can predict disease severity promptly and precisely. Unlike other markers like C-reactive protein or white blood cell count, procalcitonin (PCT) levels specifically increase in bacterial infections, which are a common cause of severe pneumonia in children. AIM To evaluate the predictive value of serum PCT in assessing pneumonia severity and clinical outcomes in under-five children. METHODS This prospective observational study was conducted in a tertiary care teaching hospital in Eastern India from August 2022 to July 2024. Children aged 2 to 59 months admitted with pneumonia underwent serum PCT estimation on day 1 and day 5 of admission. The pneumonia severity was classified as follows: (1) Very severe (intubation, shock, or death); (2) Severe (intensive care admission without very severe features and/or high-flow nasal canula); (3) Moderate (hospitalization without very severe or severe features); and (4) Mild (discharge). Correlation analysis and receiver operating characteristic (ROC) curve analysis were performed to assess the predictive utility of PCT. RESULTS Two hundred children were included. Majority were < 6 months of age, and male (64%). Children in the viral pneumonia group were significantly younger. The pneumonia severity was as follows: (1) Very severe (18%); (2) Severe (24.5%); and (3) Moderate (57.5%). Eighteen (9%) children died. On day 1, the mean ± SD level of serum PCT level for different pneumonia severity was as follows: (1) Moderate (0.47 ± 0.42); (2) Severe (2.04 ± 1.5); and (3) Very severe (4.29 ± 2.37). The differences across the groups were statistically significant (P < 0.01). By day 5, the pattern of increasing PCT levels with greater disease severity persisted: (1) Moderate (0.26 ± 0.18); (2) Severe (3.14 ± 4.1); and (3) Very severe (9.51 ± 3.62). The differences observed on day 5 were statistically significant (P < 0.01). PCT levels were significantly higher in bacterial pneumonia compared to viral and atypical pneumonia. On day 1, the AUC of PCT in predicting mortality was 0.946 (95%CI: 0.905-0.973), and on day 5, the AUC was 0.948 (95%CI: 0.908-0.975). CONCLUSION The present study found that serum PCT can predict pneumonia severity including mortality in under-five children. The PCT elevation was significantly higher in bacterial pneumonia compared to viral and atypical pneumonia.

  • Open Access

    Balanced electrolyte solution vs isotonic saline in the resuscitation of children with diabetic ketoacidosis: A randomized controlled trial

    by Sweta Sweety, Swarupa Panda, Rashmi Ranjan Das

    BACKGROUND Fluid therapy is a cornerstone in the management of diabetic ketoacidosis (DKA). Normal saline (NS, 0.9%) has traditionally been the fluid of choice; however, concerns about its association with hyperchloremic metabolic acidosis and possible development of acute kidney injury (AKI) have led to an increased interest in balanced electrolyte solutions (BES) as a potentially safer alternative. AIM To compare BES with NS in the initial resuscitation of children with DKA. METHODS This double-blind, parallel, randomized controlled trial (RCT) was conducted in the Pediatrics department of a tertiary care teaching hospital over two-year period. Children aged 5 to 14 years with DKA as defined by the “International Society for Pediatric and Adolescent Diabetes” were included. The primary objective was-the time taken to resolution of acidosis. Secondary objectives were-effect on electrolyte imbalances, development of cerebral edema or AKI, and other clinical outcomes. RESULTS Sixty patients were enrolled. The mean (SD) age of the patients was 10.7 (1.42) years, and majority were female (73.3%). The time (hour) taken for resolution of acidosis was not significantly different (P = 0.16). The NS group had a higher incidence of hyperchloremia (P = 0.09), AKI (P = 0.07), and prolonged hospitalization (P = 0.23), but all these were not statistically significant. Other outcomes were comparable in both the groups. CONCLUSION This trial did not find any significant difference between BES and NS (0.9%) in the initial resuscitation of children with DKA.


  • Open Access

    Kidney and pregnancy outcomes in pregnancy-associated atypical hemolytic uremic syndrome: A systematic review and meta-analysis

    by Priti Md Meena, Ruju Md Gala, Rashmi Ranjan Das, Vinant Md Bhargava, Yellampalli Md Saivani, Sandip Md Panda, Alok Md Mantri, Krishna Kumar Md Agrawaal

    Background: Pregnancy-associated atypical hemolytic uremic syndrome (p-aHUS) is a rare, life-threatening condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, elevated liver enzymes, and acute kidney injury. Prompt diagnosis and therapy are crucial due to the high risk of progression to chronic kidney disease (CKD), end-stage kidney disease (ESKD), and dialysis dependency, as well as significant maternal and fetal morbidity and mortality. Methods: A comprehensive literature search was conducted across EMBASE, MEDLINE, and the Cochrane CENTRAL from January 2000 to March 2024. Studies reporting on pregnancy and kidney outcomes in women diagnosed with p-aHUS were included. Results: Ten studies involving 386 pregnancies in 380 patients met the inclusion criteria for the final analysis. Renal outcomes varied, with mean creatinine levels ranging from 0.72 to 8.734 mg/dL. Dialysis was required in 66.6% of patients, and 25% developed ESKD. Maternal complications included preeclampsia (36.4%) and hemolysis, elevated liver enzymes, and low platelets syndrome (29.7%), with a 5% maternal mortality rate. Fetal complications included intrauterine fetal demise (n = 25), intrauterine growth restriction, low birth weight, and prematurity. Treatment with eculizumab significantly reduced the risk of CKD and ESKD, with a pooled risk ratio of 0.20 (95% confidence interval: 0.09–0.44) and low heterogeneity (I² = 0%, P = .43). Conclusion: This analysis highlights the severe kidney and pregnancy outcomes associated with p-aHUS. Eculizumab treatment is significantly beneficial in reducing the risk of CKD and ESKD.